LUMOSA THERAPEUTICS CO LTD

LUMOSA THERAPEUTICS CO LTD

TTPEX:6535
87.40
TWD
-6.20
(-6.62%)
-2.41EPS
13.77BMarket Cap
Mar 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.11
0.14
0.37
0.61
1.46
0.18
0.11
0.16
0.35
0.24
0.22
0.19
Basic EPS, GAAP
-1.14
-2.42
-2.81
-2.62
-2.22
-0.51
-2.04
-2.66
0.64
-3.04
-1.47
-2.6
-2.05
-2.38
Free Cash Flow per Basic Share
-0.52
-1.53
-1.77
-1.68
-0.74
-0.87
-3.22
-1.07
-3
-1.86
-2.11
-1.82
-2.17
-1.45
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.79
8.97
6.47
9.2
7.2
10.86
8.84
10.67
12.96
9.97
8.47
11.32
8.96
7.08
Tangible Book Value per Share
6.79
6.35
5.2
8.81
7.2
8.43
7.18
9.52
12.69
9.81
8.47
11.32
8.96
7.08
Basic Weighted Avg Shares
50
65
84
87
96
100
118
121
151
163
162
163
166
166
Sales/Revenue/Turnover
- -
- -
10
12
35
61
172
22
17
27
57
39
36
32
Operating Margin (%)
- -
- -
-2,667.93
-2,145.95
-554.56
-227.83
-87.17
-1,577.55
-2,478.27
-1,148.26
-659.96
-911.64
-930.77
-803.33
Depreciation Expense
4
57
104
78
43
12
39
36
32
22
23
8
11
11
Net Income, GAAP
-57
-157
-235
-230
-213
-50
-241
-323
96
-495
-238
-425
-341
-395
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-2,472.65
-1,842.43
-603.65
-83.11
-140.04
-1,489.83
552.62
-1,856.7
-418.23
-1,084.91
-950.41
-1,233.29
Working Capital
530
478
416
815
677
839
691
1,156
1,396
1,171
824
1,336
835
660
LT Debt
- -
- -
- -
- -
- -
- -
4
11
6
- -
8
4
- -
- -
Total Equity
534
706
548
872
692
1,273
1,046
1,583
2,119
1,670
1,429
1,928
1,519
1,192
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-23.07
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
5.16
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-25.35
-37.54
-32.33
-27.22
-5.13
-20.78
-24.54
5.18
-26.39
-15.71
-25.65
-19.91
-28.43

Capital Structure

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
167
167
167
Market Capitalization
23,950
16,832
13,767

Working Capital

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
905
800
773
Cash, Cash Equivalents & STI
747
633
601
Accounts Receivable, Net
5
5
9
Inventories
96
102
102
Total Current Liabilities
123
124
113
Payables & Accruals
- -
- -
- -
ST Debt
5
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.79%
2.39%
-21.18%
Free Cash Flow
47.86%
47.5%
21.7%
Net Income, GAAP
-41.26%
-147.71%
-19.83%
Sales/Revenue/Turnover
48.96%
21.51%
-8.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
9
6
20
39
2025
9
2
12
13
36
2026
4
5
9
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.71
0.41
-1.4
-0.9
-2.6
2025
-0.63
-0.89
-0.2
-0.34
-2.05
2026
-0.72
-0.97
-0.35
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Sheng Wen Yeh
Full Time Employees
39
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 3-2, Park Street Taipei TPE Taiwan 11503
IPO Date
Sep 26, 2016
Business
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological, oncological, and inflammatory diseases with unmet medical needs. The company advances its pipeline through a reSEARCH and DEVELOPMENT model, offering products including Naldebain (LT1001), a long-acting analgesic injection for postoperative pain relief that has received marketing approvals in Taiwan, Singapore, Thailand, Malaysia, and Ukraine; LT3001, a neuroprotectant in Phase II clinical trials for acute ischemic stroke; LT5001, which has completed Phase I trials for uremic pruritus; LT6001 in preclinical development for neurological disorders; and LT2003 in preclinical stages for oncology indications. Lumosa Therapeutics Co., Ltd. also engages in technology investment, consulting, service, and transfer activities. Incorporated in 2000 and headquartered in Taipei, Taiwan, the company operates primarily in Taiwan, Asia, the Americas, and Europe, targeting patients with central nervous system disorders, cancer, and inflammatory conditions. Recent developments include a global exclusive license agreement signed in April 2025 with the University of North Carolina at Chapel Hill for patented T-cell enhancement technology to bolster regenerative medicine and next-generation CAR-T therapies for solid tumors and other indications; expansion of LT3001 Phase II trials into multiple European Union countries announced in January 2024; and conclusion of LT3001 Phase II trials ahead of schedule in March 2025.